Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL16464665 | 0.83 | SLC7A5 (0.55) | LARS1CYP2D6MAPK1GBA1CYP1A2 | |
| Leucine SCHEMBL9592701 | 0.83 | SLC7A5 (0.55) | LARS1CYP2D6MAPK1GBA1CYP1A2 | |
| Leucine SCHEMBL29575582 | 0.83 | SLC7A5 (0.55) | LARS1CYP2D6MAPK1GBA1CYP1A2 | |
| Leucine SCHEMBL30462445 | 0.83 | SLC7A5 (0.55) | LARS1CYP2D6MAPK1GBA1CYP1A2 | |
| SCHEMBL5490658 | 0.82 | SLC7A5 (0.48) | LARS1MAPK1ALDH1A1KDM4E | |
| SCHEMBL8368378 | 0.82 | SLC7A5 (0.48) | LARS1MAPK1ALDH1A1KDM4E | |
| SCHEMBL15328407 | 0.82 | CYP1A2 (0.40) | LARS1NPSR1CYP2D6MAPK1GBA1 | |
| SCHEMBL16972958 | 0.78 | LARS1 (0.46) | LARS1ALDH1A1CA1CA2CA4 | |
| SCHEMBL16972956 | 0.78 | LARS1 (0.46) | LARS1ALDH1A1CA1CA2CA4 | |
| SCHEMBL31688109 | 0.78 | TDP1 (0.48) | CYP2D6MAPK1GBA1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912601-B2 | SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S | MASSACHUSETTS INST TECHNOLOGY (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7427591-B2 | Suppression of immune response via inhibition of cathepsin S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-23 | — | — | US | disclosed |
| US-7285525-B2 | Suppression of immune response via inhibition of cathepsin S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050095248-A1 | Suppression of immune response via inhibition of cathepsin S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-05-05 | — | — | US | disclosed |
| US-20050080010-A1 | Suppression of immune response via inhibition of cathepsin S | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-14 | — | — | US | disclosed |
| EP-1400530-A1 | Suppression of immune response via inhibition of cathepsin S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-0912601-B1 | SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S | MASSACHUSETTS INST TECHNOLOGY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030166534-A1 | Suppression of immune response via inhibition of cathepsin S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-09-04 | — | — | US | disclosed |
| US-6608030-B1 | Suppression of immune response via inhibition of cathepsin S | BRIGHAM & WOMEN'S HOSPITAL, INC. | 2003-08-19 | — | — | US | disclosed |
| EP-0912601-A1 | SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997040066-A1 | SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-10-30 | — | — | WO | disclosed |